





## **Analogue Searching increases X-ray Success**





#### **FindAnalogues**





Mol Wt or heavy atom limit per query structure

Total hits per sub-query (most similar or lowest mol wt)


# Multi parameter decision making






Calculated Properties			
Regno			
mw	185.23		
clogP	1.2		
tPSA	41.57		
NumHeavy	14		
Acceptors	2		
Donors	1		
Rotbonds	2		

Measured Properties			
Regno	la second		
HPGDS pIC50	4.8		
LigEff	0.47		
LigEffAT	0.46		
CLND_sol	>=391 uM		
CHROM_LOGD_PH74	1.6		
HSA_PCT_BIND	84.2		
AGP_PCT_BIND	53.0		




Summary Comments					
Properties of Validated Hit Series	Current data plC50	LE	LLEAT	Does the series hit the criteria	Comments
LE between 0.3 & 4.3					
Best in cluster					
Clear X-ray binding mode					
Astex rule of 3					
Synthetic tractability					
Expectation that elaborated molecules will be patentable					
Off target effects					
EXP					
Stability data					



# **Active site mapping (eg GRID)**





AstexViewer2 documentation

Help (only visible to CSC)
Help (more widely visible)

Contact us

PSV owners

PSV Front Page

AstexViewer help

<u>PSILO</u>

CSC Community

### Hit prioritisation



- Hit validation? (active in orthogonal assays)
- Judge the series not the hit
- Generate as much data as possible to inform decisions
- Potency a consideration, but not the primary factor
- Consider potential for growth
  - Growth vectors
  - Known structures/SAR
  - Hot spotting tools
- Synthetic tractability
- Chemical stability
- Not worried about selectivity at this point

### **Fragment to Lead**



- Collect all screening data before committing to work on a series
- Screen available analogues to generate SAR before starting chemistry
- Core optimisation (most LE starting point)
- Grow slowly
- Monitor properties (use of LE, LLE, etc.)
- Use of structure based design to drive chemistry plans
- Growing and hybridisation preferred to linking fragments
- Avoid flat highly aromatic compounds

## Was my change "worthwhile"?



 Required potency change to maintain LLE<sub>AT</sub> for common aromatic substituents

